findmyKOL
Clinical trialNCT05755932CompletedPhase 3Interventional

Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants

SponsorAstraZenecaEnrollment35Mucociliary Clearance
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United Kingdom
  • Research Site

    Glasgow, United Kingdom

United States
  • Research Site

    Kansas City, Kansas, United States

  • Research Site

    Baltimore, Maryland, United States

  • Research Site

    Chapel Hill, North Carolina, United States

  • Research Site

    Pittsburgh, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
14 Jun 2023
Primary completion
22 Jul 2024
Completion
22 Jul 2024
Last update posted
25 Feb 2026
Registered enrollment
35
Registry id
NCT05755932

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.